A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07141199
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-8736 — DRUG
    Intravenous (IV) Infusion
  • Placebo — DRUG
    IV Infusion

Study Details

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

Key Dates

Start date
Sep 2, 2025
Status verified
Apr 2026
Primary completion
Mar 23, 2026
Completion
Mar 23, 2026

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Group 1: Dose A of ABBV-8736
    Participants will receive intravenous (IV) ABBV-8736 dose A every 2 weeks for a total of 3 doses.
  • Placebo Comparator: Group 1: Dose A of ABBV-8736 Placebo
    Participants will receive IV ABBV-8736 placebo dose A every 2 weeks for a total of 3 doses.
  • Experimental: Group 2: Dose B of ABBV-8736
    Participants will receive IV ABBV-8736 dose B every 2 weeks for a total of 3 doses.
  • Placebo Comparator: Group 2: Dose B of ABBV-8736 Placebo
    Participants will receive IV ABBV-8736 placebo dose B every 2 weeks for a total of 3 doses.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Approximately 113 Days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 277377GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies